SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT01860534

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

"Eye Protection After Mydriatic Use for ROP Screening: Impact on Vitals Signs and Pain Scores"

Pupillary dilation induced by mydriatic agents during Retinopathy of Prematurity exams can persist for hours. Despite regular use of eye protection for mydriatic-induced light sensitivity for infants, children and adults, eye protection after mydriasis has not been addressed in neonates. This study examines the use of eye patches to protect the dilated pupil from light exposure and their impact on vital signs and pain scores. prevents tachycardia, tachypnea and discomfort in neonates after ROP screening.

NCT01860534 Light Sensitivity
MeSH: Photophobia
HPO: Photophobia

1 Interventions

Name: eye covers

Description: The infants were randomly assigned by alternating enrolled patients between one of two groups prior to their first ROP screening. Group A was patched for their first ROP exam and then unpatched for their second exam while group B was unpatched for their first ROP exam and unpatched for their second exam. The patched subjects had eye covers after their eyes were dilated, and the unpatched subjects had comfort measures similar to the patched subjects but their eyes were not covered. The patching of the eyes was done in the same way that it is done for eye protection during phototherapy, with the same model of eye patches (Natus biliband) and with the same nursing care.

Type: Behavioral

Eye patches covers


Primary Outcomes

Description: At 3 times (pre-mydriasis, 1 hour and 3 hours after Cyclomydril drops), subjects were exposed to ambient lighting for a period of five minutes. This usually entailed removing isolette covers and exposing the patient to the ambient room light. During this time, pain and vital signs were recorded every minute. Heart rate was recorded directly from their cardio-respiratory monitor (Agilent M1106C). The mean of the five recorded values for each variable was used

Measure: Heart Rate

Time: pre-mydriasis, 1 hour and 3 hours after mydriatic drops

Secondary Outcomes

Description: At 3 times (pre-mydriasis, 1 hour and 3 hours after Cyclomydril drops), subjects were exposed to ambient lighting for a period of five minutes. This usually entailed removing isolette covers and exposing the patient to the ambient room light. During this time, pain and vital signs were recorded every minute. Respiratory rate was recorded directly from their cardio-respiratory monitor (Agilent M1106C). The mean of the five recorded values for each variable was used

Measure: Respiratory Rate

Time: pre-mydriasis, 1 hour and 3 hours after mydriatic drops

Description: At 3 times (pre-mydriasis, 1 hour and 3 hours after Cyclomydril drops), subjects were exposed to ambient lighting for a period of five minutes. This usually entailed removing isolette covers and exposing the patient to the ambient room light. During this time, pain and vital signs were recorded every minute. Oxygen percent saturation was recorded directly from their cardio-respiratory monitor (Agilent M1106C). The mean of the five recorded values for each variable was used

Measure: Oxygen Percent Saturation

Time: pre-mydriasis, 1 hour and 3 hours after mydriatic drops

Description: At 3 times (pre-mydriasis, 1 hour and 3 hours after Cyclomydril drops), subjects were exposed to ambient lighting for a period of five minutes. This usually entailed removing isolette covers and exposing the patient to the ambient room light. During this time, pain and vital signs were recorded every minute. Pain scores were recorded by direct observation using the Neonatal and Infant Pain Scale (NIPS). The mean of the five recorded values for each variable was used. NIPS scoring consists of 6 measures associated with neonatal or infant pain, each with a range of 0-7 with low scores (0-2) associated with no pain and scores > to 4 associated with severe pain. Maximum scoring would be 42 for severe pain and minimal being 0 for no pain. The six measures on NIPS include: facial expression, crying, breathing patterns, arm movements, leg movements and state of arousal.

Measure: Pain

Time: pre-mydriasis, 1 hour and 3 hours after mydriatic drops

Purpose: Supportive Care

Allocation: Randomized

Crossover Assignment


There is one SNP

SNPs


1 M1106C

Heart rate was recorded directly from their cardio-respiratory monitor (Agilent M1106C). --- M1106C ---

Respiratory rate was recorded directly from their cardio-respiratory monitor (Agilent M1106C). --- M1106C ---

Oxygen percent saturation was recorded directly from their cardio-respiratory monitor (Agilent M1106C). --- M1106C ---



HPO Nodes


HPO:
Photophobia
Genes 206
SLC24A5 IL10 SPATA7 CERKL IL12A PRPF31 PCYT1A LRAT IFT140 ARL2BP ERCC2 MAK AHI1 ERCC3 ABCA4 ERCC4 ERCC5 PDE6A ERCC6 HK1 PDE6C PDE6G PDE6H IMPDH1 HLA-A HLA-B PDE6B ERAP1 MAPT IFT172 KCNV2 KIZ ADAM9 CDHR1 GJB6 TTLL5 DHX38 RNF113A SLC6A19 MC1R CHST6 BBS2 DHDDS IKZF1 RGS9 PRPF6 OPN1MW AGBL5 MFRP LYST DDB2 TUB KLRC4 ITGB6 ST14 MEFV STAT4 TULP1 OVOL2 NOD2 TYR ARL6 TTC8 PROM1 TIMM8A NEK2 GJB2 RAB28 SAG PNPLA6 MBTPS2 ALMS1 CEP78 KLHL7 REEP6 ATXN7 FAM161A CABP4 SCN1A KCNJ13 POC1B PITX3 MITF SCAPER FSCN2 AIPL1 AHR AHSG PRCD GTF2H5 ANTXR1 CCR1 C4A PLCD1 SEMA4A GNAT2 MERTK ALDH3A2 GNB3 ITM2B USH2A CLRN1 CNGB1 CNGA1 CNGA3 AP3D1 TAT CFAP410 IL23R CA4 IMPG2 FOXE3 FOXC2 RPGRIP1 CACNA1F KRT3 BEST1 NR2E3 KRT12 COL17A1 OFD1 NMNAT1 NRL POLA1 POLH RBP3 HGSNAT OPN1LW AIRE KIAA1549 GPR143 RDH5 RDH12 POMGNT1 PRPH2 ARHGEF18 NLRP1 PCARE SLC39A4 RTN4IP1 DRAM2 XPA OCA2 XPC IDH3B AP3B1 PRPF8 FAS RAX2 MCOLN1 RGR SLC1A3 SLC7A14 NLRP3 RHO CRB1 CRX RLBP1 PIKFYVE TGFBI UNC119 CNNM4 CRYGC ATF6 GTF2E2 EYS ARL3 CACNA2D4 DKK1 GUCA1A GUCA1B IFT88 PRPF4 PRPF3 IL12A-AS1 TP63 ZNF408 CEP250 RGS9BP GUCY2D CNGB3 HPS6 TLR4 PITPNM3 MPLKIP WNT10A UBAC2 ROM1 SLC45A2 RP9 LTBP2 RP1 HADHA RP2 RPGR RIMS1 CTNS C8ORF37 HARS TOPORS LRMDA TACSTD2 RPE65 SNRNP200 PCNA ZNF513